share_log

科濟藥業-B：截至2024年2月29日止月份之股份發行人的證券變動月報表

CARSGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

香港交易所 ·  Mar 6 07:06
Summary by Moomoo AI
科濟藥業-B（02171.HK）於2024年3月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年2月29日的情況。報告顯示，公司的法定/註冊股本結存維持不變，為200,000,000,000股，每股面值0.00000025美元，總額為50,000美元。此外，根據2019年股權激勵計劃和首次公開發售後購股權計劃，公司可能發行的新股份數量為3,799,473股。報告中未顯示本月有新股份發行，並確認所有發行的證券均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
科濟藥業-B（02171.HK）於2024年3月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年2月29日的情況。報告顯示，公司的法定/註冊股本結存維持不變，為200,000,000,000股，每股面值0.00000025美元，總額為50,000美元。此外，根據2019年股權激勵計劃和首次公開發售後購股權計劃，公司可能發行的新股份數量為3,799,473股。報告中未顯示本月有新股份發行，並確認所有發行的證券均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
KOCHI PHARMACEUTICAL-B (02171.HK) FILED ITS LATEST MONTHLY SECURITIES FLUCTUATION REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON MARCH 6, 2024, COVERING THE SITUATION AS OF FEBRUARY 29, 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL WAS UNCHANGED AT 200,000,000,000 SHARES WITH A FACE VALUE OF $0.000025 PER SHARE FOR A TOTAL OF $50,000. In addition, the number of new shares that the Company may issue is 3,799,473 shares under the Equity Incentive Program in 2019 and the Initial Public Offering Possession Option Plan. The report does not show any new share issuance this month and confirms that all securities issued have been approved by the Board and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
KOCHI PHARMACEUTICAL-B (02171.HK) FILED ITS LATEST MONTHLY SECURITIES FLUCTUATION REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON MARCH 6, 2024, COVERING THE SITUATION AS OF FEBRUARY 29, 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL WAS UNCHANGED AT 200,000,000,000 SHARES WITH A FACE VALUE OF $0.000025 PER SHARE FOR A TOTAL OF $50,000. In addition, the number of new shares that the Company may issue is 3,799,473 shares under the Equity Incentive Program in 2019 and the Initial Public Offering Possession Option Plan. The report does not show any new share issuance this month and confirms that all securities issued have been approved by the Board and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more